Skip to main content

Compare Stocks

Date Range: 

 ImmunovantAlloVirREGENXBIOKrystal BiotechSangamo Therapeutics
SymbolNASDAQ:IMVTNASDAQ:ALVRNASDAQ:RGNXNASDAQ:KRYSNASDAQ:SGMO
Price Information
Current Price$15.50$24.00$36.14$67.93$10.85
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.51.61.51.3
Analysis Score3.53.53.43.53.4
Community Score3.73.52.72.52.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.71.70.8
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$44.93$49.25$62.50$101.00$20.50
% Upside from Price Target189.89% upside105.21% upside72.94% upside48.68% upside88.94% upside
Trade Information
Market Cap$1.52 billion$1.56 billion$1.54 billion$1.51 billion$1.56 billion
BetaN/AN/A1.281.21.97
Average Volume1,290,661338,141431,114139,6111,402,479
Sales & Book Value
Annual RevenueN/AN/A$35.23 millionN/A$102.43 million
Price / SalesN/AN/A43.61N/A15.24
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.45 per shareN/A$12.23 per share$11.72 per share$3.73 per share
Price / BookN/AN/A2.96N/A2.91
Profitability
Net Income$-66,390,000.00N/A$-94,730,000.00$-19,090,000.00$-95,190,000.00
EPS($1.54)N/A($3.26)($1.20)($0.85)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-63.13%N/A-51.51%
Return on Equity (ROE)-34.80%N/A-21.73%-10.72%-16.32%
Return on Assets (ROA)-32.38%N/A-18.74%-10.40%-9.85%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio35.15%28.40%6.08%39.96%5.67%
Quick Ratio35.15%28.40%6.08%39.96%5.67%
Ownership Information
Institutional Ownership Percentage40.21%32.07%75.23%73.05%57.69%
Insider Ownership Percentage0.24%1.00%14.10%27.40%1.80%
Miscellaneous
Employees425330675413
Shares Outstanding97.97 million65.11 million42.51 million22.21 million143.88 million
Next Earnings Date7/5/2021 (Estimated)9/1/2021 (Estimated)8/5/2021 (Estimated)8/9/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Wasatch Global on Sangamo (SGMO): “We Remain Optimistic About its Future Prospects”Wasatch Global on Sangamo (SGMO): “We Remain Optimistic About its Future Prospects”
finance.yahoo.com - May 12 at 6:57 PM
Let’s Jump into the Sangamo Therapeutics Inc. (NASDAQ:SGMO) Stock ForecastLet’s Jump into the Sangamo Therapeutics Inc. (NASDAQ:SGMO) Stock Forecast
marketingsentinel.com - May 12 at 1:57 PM
Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at Royal Bank of CanadaSangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at Royal Bank of Canada
americanbankingnews.com - May 10 at 11:02 AM
Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Royal Bank of CanadaSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Royal Bank of Canada
americanbankingnews.com - May 10 at 11:02 AM
Zacks: Brokerages Expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Will Post Earnings of -$0.27 Per ShareZacks: Brokerages Expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Will Post Earnings of -$0.27 Per Share
americanbankingnews.com - May 7 at 9:22 AM
Sangamo Therapeutics Inc. [SGMO] moved down -8.54: Why It’s ImportantSangamo Therapeutics Inc. [SGMO] moved down -8.54: Why It’s Important
dbtnews.com - May 6 at 6:28 PM
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call TranscriptSangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 8:27 AM
Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Down 4.9% After Earnings MissSangamo Therapeutics (NASDAQ:SGMO) Stock Price Down 4.9% After Earnings Miss
americanbankingnews.com - May 5 at 12:37 PM
Sangamo Therapeutics (NASDAQ:SGMO) Releases  Earnings Results, Misses Estimates By $0.03 EPSSangamo Therapeutics (NASDAQ:SGMO) Releases Earnings Results, Misses Estimates By $0.03 EPS
americanbankingnews.com - May 4 at 11:46 PM
Sangamo: Q1 Earnings Snapshot | Raleigh News & ObserverSangamo: Q1 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - May 4 at 6:35 PM
Sangamo: Q1 Earnings SnapshotSangamo: Q1 Earnings Snapshot
sfgate.com - May 4 at 6:35 PM
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial ResultsSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
markets.businessinsider.com - May 4 at 6:35 PM
Sangamo Therapeutics, Inc. 2021 Q1 - Results - Earnings Call PresentationSangamo Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 4 at 6:31 PM
Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Royal Bank of CanadaSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Royal Bank of Canada
americanbankingnews.com - May 3 at 5:32 PM
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is A Blank Check For GrowthSangamo Therapeutics, Inc. (NASDAQ:SGMO) Is A Blank Check For Growth
stocksregister.com - May 1 at 10:47 AM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Flexion Therapeutics (FLXN) and BioVie (BIVI)Analysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Flexion Therapeutics (FLXN) and BioVie (BIVI)
smarteranalyst.com - April 28 at 2:11 PM
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and WebcastSangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
finance.yahoo.com - April 27 at 7:18 PM
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell TherapySangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
finance.yahoo.com - April 27 at 7:18 PM
Sangamo Therapeutics (NASDAQ:SGMO) Upgraded at Zacks Investment ResearchSangamo Therapeutics (NASDAQ:SGMO) Upgraded at Zacks Investment Research
marketbeat.com - April 23 at 3:30 AM
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare DiseaseSangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
finance.yahoo.com - March 25 at 10:37 AM
Sangamo Therapeutics Shares Cross Below 200 DMASangamo Therapeutics Shares Cross Below 200 DMA
nasdaq.com - March 24 at 8:05 PM
What’s Next After The 15% Rally For Sangamo Therapeutics Stock Last Week?What’s Next After The 15% Rally For Sangamo Therapeutics Stock Last Week?
forbes.com - March 23 at 2:02 PM
First Week of November 19th Options Trading For Sangamo Therapeutics (SGMO)First Week of November 19th Options Trading For Sangamo Therapeutics (SGMO)
nasdaq.com - March 19 at 2:28 PM
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell DiseaseSangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
finance.yahoo.com - March 17 at 6:11 PM
What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.s (NASDAQ:SGMO) Share Registry?What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Registry?
finance.yahoo.com - March 9 at 2:10 PM
Revisting Sangamo TherapeuticsRevisting Sangamo Therapeutics
seekingalpha.com - March 8 at 10:19 PM
DateCompanyBrokerageAction
5/10/2021ImmunovantHC WainwrightLower Price Target
2/16/2021ImmunovantStifel NicolausReiterated Rating
2/3/2021ImmunovantRaymond JamesLower Price Target
2/3/2021ImmunovantSVB LeerinkLower Price Target
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
11/12/2020ImmunovantChardan CapitalBoost Price Target
10/28/2020ImmunovantUBS GroupInitiated Coverage
10/12/2020ImmunovantGuggenheimInitiated Coverage
10/6/2020ImmunovantLifesci CapitalReiterated Rating
10/2/2020ImmunovantCSFBInitiated Coverage
4/26/2021AlloVirMorgan StanleyBoost Price Target
2/11/2021AlloVirPiper SandlerBoost Price Target
8/24/2020AlloVirJPMorgan Chase & Co.Initiated Coverage
1/7/2019AlloVirBank of AmericaUpgrade
7/10/2018AlloVirThe Goldman Sachs GroupInitiated Coverage
1/20/2021REGENXBIORoyal Bank of CanadaBoost Price Target
9/24/2020REGENXBIOBarclaysLower Price Target
11/11/2019REGENXBIOEvercore ISIReiterated Rating
2/9/2021Krystal BiotechJonestradingInitiated Coverage
11/11/2020Krystal BiotechB. RileyReiterated Rating
5/4/2020Krystal BiotechWilliam BlairReiterated Rating
11/5/2019Krystal BiotechCowenReiterated Rating
3/3/2021Sangamo TherapeuticsWells Fargo & CompanyLower Price Target
7/7/2020Sangamo TherapeuticsSunTrust BanksInitiated Coverage
6/19/2020Sangamo TherapeuticsWedbushReiterated Rating
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.